• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ITPA Gene Record

  • Summary
  • Interactions
  • Claims
  • ITPA 3704

    Alternate Names:

    3704
    INOSINE TRIPHOSPHATASE
    ITPA
    C20orf37
    HLC14-06-P
    ITPase
    My049
    NTPase
    dJ794I6.3
    147520
    6176
    ENSG00000125877
    OTTHUMG00000031738
    PA29973
    Q9BY32
    DEE35
    Inosine triphosphate pyrophosphatase

    Gene Info:

    Gene Biotype PROTEIN_CODING
    (0 More Sources)

    Gene Categories: Category Details

    ENZYME

    Publications:

    Kamal AM et al., 2016, Clinical importance of pharmacogenetics in the treatment of hepatitis C virus infection., Rom J Morphol Embryol
    Morio K et al., 2016, Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C., Hepatol Res
    About F et al., 2015, Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study., PLoS One
    Maan R et al., 2015, ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection., PLoS One
    Pineda-Tenor D et al., 2015, Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis., J Transl Med
    Ampuero J et al., 2015, Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment., J Clin Virol
    Cusato J et al., 2015, VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia., Pharmacogenet Genomics
    Seto WK et al., 2013, Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection., J Viral Hepat
    Ogawa E et al., 2013, Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy., J Hepatol
    Azakami T et al., 2011, Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy., J Med Virol
    Thompson AJ et al., 2011, Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR., Hepatology
    Suzuki F et al., 2011, Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir., Hepatology
    Ochi H et al., 2010, ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients., Gastroenterology
    Thompson AJ et al., 2010, Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction., Gastroenterology
    Fellay J et al., 2010, ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C., Nature
    Hareedy MS et al., 2015, Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients., Pharmacogenomics
    Adam de Beaumais T et al., 2011, Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy., Br J Clin Pharmacol
    Stocco G et al., 2009, Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia., Clin Pharmacol Ther
    López-Rodríguez R et al., 2018, Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritis., Pharmacogenomics J
    Jenko B et al., 2017, Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis., Pharmacogenomics J
    Dervieux T et al., 2009, Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis., Pharmacogenet Genomics
    Wessels JA et al., 2006, Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis., Arthritis Rheum
    Steponaitiene R et al., 2016, TPMT and ITPA genetic variants in Lithuanian inflammatory bowel disease patients: Prevalence and azathioprine-related side effects., Adv Med Sci
    Zabala-Fernández W et al., 2011, A pharmacogenetics study of TPMT and ITPA genes detects a relationship with side effects and clinical response in patients with inflammatory bowel disease receiving Azathioprine., J Gastrointestin Liver Dis
    Okada Y et al., 2009, Pro32Thr polymorphism of inosine triphosphate pyrophosphatase gene predicts efficacy of low-dose azathioprine for patients with systemic lupus erythematosus., Clin Pharmacol Ther
    Hawwa AF et al., 2008, Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine., Br J Clin Pharmacol
    Ansari A et al., 2008, Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease., Aliment Pharmacol Ther
    Zelinkova Z et al., 2006, Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression., Clin Gastroenterol Hepatol
    Breen DP et al., 2005, Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation., Liver Transpl
  • RIBAVIRIN   ITPA

    Interaction Score: 7.73

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27833958 26916827 26670100 26441325 26438033 26071337 25713999 23730840 23707372 21503919 21274861 21246582 20637204 20547162 20173735


    Sources:
    PharmGKB

  • AZATHIOPRINE   ITPA

    Interaction Score: 4.95

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26674571 21961091 19129747 18662289 18616518 16431304 15973722


    Sources:
    PharmGKB

  • MERCAPTOPURINE   ITPA

    Interaction Score: 1.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26237184 21395650 18685564


    Sources:
    PharmGKB

  • METHOTREXATE   ITPA

    Interaction Score: 0.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29520081 27217051 26237184 19858780 16947783


    Sources:
    PharmGKB

  • Ensembl: ENSG00000125877

    • Version: 101_38

    Alternate Names:
    ITPA Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • PharmGKB: ITPA

    • Version: 18-August-2020

    Alternate Names:
    PA29973 PharmGKB ID

    Gene Info:

    Publications:
    Hareedy MS et al., 2015, Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients., Pharmacogenomics
    Dervieux T et al., 2009, Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis., Pharmacogenet Genomics
    Jenko B et al., 2017, Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis., Pharmacogenomics J

  • HumanProteinAtlas: ITPA

    • Version: 19.3

    Alternate Names:
    ENSG00000125877 Ensembl Gene ID
    C20orf37 Human Protein Atlas Gene Synonym
    dJ794I6.3 Human Protein Atlas Gene Synonym

    Gene Info:

    Gene Categories:
    ENZYME

    Publications:

  • Pharos: ITPA

    • Version: 01-February-2022

    Alternate Names:
    Inosine triphosphate pyrophosphatase Gene Name
    Q9BY32 UniProt ID

    Gene Info:

    Gene Categories:
    ENZYME

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21